AbbVie announced an interim analysis of an ongoing Phase III, open-label 156-week extension study evaluating the long-term safety and tolerability of oral atogepant for the prevention of migraine in participants with chronic or episodic migraine.
Eli Lilly and Company announced that the National Institute for Health and Care Excellence (NICE) has recommended Emgality (galcanezumab) as an option for the prevention of migraine in adults with episodic and chronic migraine.
NuPathe Inc.has announced that the FDA has approved Zecuity (sumatriptan iontophoretic transdermal system) for the acute treatment of Migraine with...
This guideline provides recommendations on the pharmacological management of adults with acute migraine, and prophylaxis for patients with episodic or chronic migraine or medication overuse headache.
AbbVie announced at Health Canada has approved Qulipta (atogepant) for the prevention of episodic migraine (< 15 migraine days per month) in adults
Purpose of review: Migraine is a primary headache disorder and one of the most common and disabling neurological diseases worldwide.
This is an interventional, multi-regional, multi-site, randomized, double-blind, placebo-controlled Phase III study, to confirm the efficacy and safety of eptinezumab in participants with chronic migraine who are eligible for preventive treatment.
Axsome Therapeutics, Inc. announced that AXS 07 substantially and significantly eliminated migraine pain, and substantially and significantly prevented progression of migraine pain intensity in the INTERCEPT Phase III trial of AXS 07 in the early treatment of migraine.
Join Professor Mario Peres, founder of the Sao Paulo Headache Center in Sao Paulo, Brazil, in exploring emerging real-world evidence for CGRP mAbs in preventing migraine.